Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100

- February 11th, 2019

Aduro Biotech (NASAQ:ADRO) has announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 for the treatment of refractory . melanoma. As quoted in the press release: The multicenter trial (see www.clinicaltrials.gov, identifier: NCT02675439), which is part of an ongoing research and development collaboration with Novartis, will enroll advanced melanoma … Continued

Aduro Biotech (NASAQ:ADRO) has announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 for the treatment of refractory . melanoma.

As quoted in the press release:

The multicenter trial (see www.clinicaltrials.gov, identifier: NCT02675439), which is part of an ongoing research and development collaboration with Novartis, will enroll advanced melanoma patients who have relapsed after or are refractory to treatment with anti-PD-1 antibodies, nivolumab or pembrolizumab.

“We are pleased to initiate this study evaluating ADU-S100 with ipilimumab in a homogeneous patient population. Despite recent advancements in treating earlier stages of melanoma, the relapsed and refractory patient segment remains underserved due to a lack of therapeutic options. Based on their potential synergistic activity, ADU-S100 in combination with an anti-CTLA-4 antibody could generate a systemic adaptive immune response in patients with late-stage melanoma,” commented Stephen Isaacs, chairman, president and chief executive officer of Aduro Biotech. “As demonstrated leaders in the STING pathway, we are committed to build upon the growing body of data we’ve generated thus far, including encouraging clinical signals demonstrated by ADU-S100 as a single agent and in combination with spartalizumab, an investigational anti-PD-1 antibody.”

The protocol for investigation of ADU-S100 as a single agent was amended to include evaluation of ADU-S100 in combination with ipilimumab. During the ongoing dose escalation phase of the trial, ipilimumab will be administered at its approved dose and schedule, while the dose of ADU-S100 will be escalated. The dose expansion phase of the trial will evaluate the optimized dose of ADU-S100 in combination with ipilimumab in two expansion cohorts that will enroll patients with cutaneously and viscerally accessible melanoma.

Click here to read the full press release.

Looking for great biotech companies?

 
Find new opportunities and valuable news in your free report
 

 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *